Site Search
Professionals 513 results
Capabilities 89 results
Practice Area
Our capital markets and securities attorneys represent U.S. and international issuers, institutional investors, underwriters, and placement agents in a wide variety of public and private offerings of debt and equity securities.
Practice Area
Winston & Strawn’s private equity attorneys provide strategic advice and legal counsel to middle-market private equity funds, hedge funds, family offices, real estate funds, alternative asset managers, portfolio companies, and institutional investors. We have one of the broadest and most active national middle-market private equity practices in the U.S.
Practice Area
Secondaries & Liquidity Solutions
Winston & Strawn’s Secondaries and Liquidity Solutions group delivers market-leading counsel to clients navigating the evolving landscape of private fund liquidity, secondaries transactions, and bespoke capital solutions. Our multidisciplinary team advises private fund sponsors, institutional investors, and asset managers on the full spectrum of private investment fund secondary market activity, from traditional LP portfolio sales to complex GP-led transactions and innovative liquidity structures. Our attorneys are consistently recognized by leading private equity corporate publications, including Chambers, Legal 500, and others.
Experience 316 results
Experience
|April 27, 2026
Winston Represents Initial Purchasers in GABX Leasing’s $1 Billion Inaugural Senior Notes Offering
Winston & Strawn LLP represented the initial purchasers, BofA Securities, Inc., MUFG Securities Americas Inc., SMBC Nikko Securities America, Inc., and Wells Fargo Securities, LLC, in connection with GABX Leasing LLC’s inaugural $1 billion Rule 144A offering of senior notes, with GATX Corporation as guarantor. The offering consisted of $500 million of 4.625% Senior Notes due 2031 and $500 million of 5.300% Senior Notes due 2036. GABX Leasing LLC is a joint venture between GATX Corporation and Brookfield Infrastructure Partners L.P. and its institutional partners, formed in connection with the approximately $4.2 billion acquisition of a portfolio of approximately 101,000 railcars from Wells Fargo. This financing represents a key component of the joint venture’s capital structure and supports the continued expansion of one of the largest railcar leasing platforms in North America. This transaction underscores Winston’s market leading capital markets practice and its continued role advising global financial institutions on complex, large scale financings, particularly those supporting critical infrastructure and transportation assets.
Experience
|March 30, 2026
Winston & Strawn LLP Paris advised NextStage AM on its investment in Evoluderm, a leading French player in the hygiene and beauty sector. This growth capital transaction, led by NextStage AM as a minority investor, will provide Nathalie and Gabriel Aiach – founders and majority shareholders with over 20 years’ expertise in the cosmetics sector – with the means to accelerate their ambition: to make Evoluderm an iconic brand, ranking among the world leaders in accessible, high-quality beauty. Founded in 2004, Evoluderm has established itself over the last five years as a benchmark in the health and beauty sector, distributed in over 100 countries. The brand has thus experienced remarkable growth, with turnover tripling over the last three years to reach nearly €40 million in 2025. With the support of NextStage AM, Evoluderm is embarking on an ambitious development plan to consolidate its position as a market leader.
Experience
|March 25, 2026
Winston & Strawn LLP served as counsel to BitMine Immersion Technologies, Inc. in connection with its acquisition of Pier Two Holdings Pty Ltd, advancing BitMine’s strategy to scale its institutional Ethereum staking platform, the Made in America Validator Network (MAVAN). The acquisition positions BitMine, the world’s largest Ethereum Digital Asset Treasury (DAT) company and the second largest DAT globally, to expand its digital asset management and staking services.
Insights & News 5,230 results
Capital Markets & Securities Law Watch
|April 27, 2026
|4 Min Read
SEC Grants Exemptive Relief for Shortened Equity Tender Offers
On April 16, 2026, the Securities and Exchange Commission’s (the SEC) Office of Mergers and Acquisitions in the Division of Corporation Finance (the Division) issued an exemptive order (the Order) permitting certain tender offers for equity securities to remain open for a minimum of 10 business days rather than the standard 20 business days, subject to strict conditions designed to preserve investor protections.
In the Media
|April 24, 2026
|1 Min Read
Aimee Fagan Joins Winston in Dallas
Winston & Strawn recently announced that Aimee Fagan has joined the firm’s Dallas office as a partner in the Litigation Department and a member of the Intellectual Property Practice. Aimee is a first-chair trial lawyer whose practice focuses on intellectual property and complex commercial litigation. She represents clients in high-stakes disputes, with significant experience in technology and IP matters, particularly within the energy sector, as well as across the technology, financial services, private equity, medical, and retail industries.
In the Media
|April 24, 2026
|1 Min Read
The American Lawyer Spotlights Winston’s Momentum with Six Partner Additions
Winston was featured in The American Lawyer following the firm’s addition of six lateral partners across Chicago, New York, Washington, D.C., and Dallas in April, further strengthening key practices including leveraged finance, investigations, intellectual property, and appellate litigation.
Other Results 103 results
Law Glossary
What Is Consumer Marketing Law?
Consumer marketing law is a broad legal segment dealing with federal and state statutes, along with government regulations, established to ensure that marketing and advertising are truthful. Federal law states that no form of advertising, including online advertising, can be deceptive. Marketing claims must also be evidence-based.
Law Glossary
What Statutes and Regulations Govern the Approval and Marketing of Biosimilars?
Congress passed the Biologics Price Competition and Innovation Act of 2009 (BPCIA) in 2010 an amendment of the Public Health Services Act. The BPCIA is codified at 42 U.S.C. § 262.
Site Content